The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology
Frontiers | Value of Carbohydrate Antigen 19-9 in Predicting Response and Therapy Control in Patients with Metastatic Pancreatic Cancer Undergoing First-Line Therapy | Oncology
![PDF] Application of biochemical markers CA 19-9, CEA and C-reactive protein in diagnosis of malicious and benign pancreatic tumors | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a96fc01f495907ea18214fdc7db7ffd9b210d72c/2-TableI-1.png "PDF] Application of biochemical markers CA 19-9, CEA and C-reactive protein in diagnosis of malicious and benign pancreatic tumors | Semantic Scholar")
PDF] Application of biochemical markers CA 19-9, CEA and C-reactive protein in diagnosis of malicious and benign pancreatic tumors | Semantic Scholar
Frontiers | Value of Carbohydrate Antigen 19-9 in Predicting Response and Therapy Control in Patients with Metastatic Pancreatic Cancer Undergoing First-Line Therapy | Oncology
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology
SciELO - Brasil - Further evidence of the prognostic role of pretreatment levels of CA 19-9 in advanced pancreatic cancer Further evidence of the prognostic role of pretreatment levels of CA 19-9
Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies
CA 19-9 as a serum marker in urothelial carcinoma Pall M, Iqbal J, Singh SK, Rana SV - Urol Ann
Tumor Marker Control | Fujirebio
Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas – A retrospective tumor marker prognostic study - ScienceDirect
CA19–9 decrease and survival according to platelet level in patients with advanced pancreatic cancer | BMC Cancer | Full Text
Tumor Marker:- Part 7 - CA 125 and CA 19-9 - Labpedia.net
Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas – A retrospective tumor marker prognostic study - ScienceDirect
Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine | British Journal of Cancer
Clinical Value of Serum CEA, CA 19-9, CA 242 and AFP in Diagnosis of Gastrointestinal Tract Cancers - SciAlert Responsive Version
Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies
Tumor Marker CA 19-9 for Assessing Pancreatic Cancer Response - Cancer Therapy Advisor
SciELO - Brasil - Further evidence of the prognostic role of pretreatment levels of CA 19-9 in advanced pancreatic cancer Further evidence of the prognostic role of pretreatment levels of CA 19-9
Pancreatic cancer and predictors of survival: comparing the CA 19-9/bilirubin ratio with the McGill Brisbane Symptom Score - ScienceDirect
O noua sosire Silitor perturbație ca 19 9 marker - rapidosdelriobaker.com
References in How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects? - Digestive and Liver Disease
![PDF] Assessing Prognosis in Metastatic Pancreatic Cancer by the Serum Tumor Marker CA 19-9: Pretreatment Levels or Kinetics during Chemotherapy? | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/f7bb4eb6de25f6ecb9323cbef8061896f020a0da/2-Table1-1.png "PDF] Assessing Prognosis in Metastatic Pancreatic Cancer by the Serum Tumor Marker CA 19-9: Pretreatment Levels or Kinetics during Chemotherapy? | Semantic Scholar")